Hope S. Rugo
AuthID: R-00G-Q89
1
TÃTULO: Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
AUTORES: Rugo, HS; Im, SA; Cardoso, F; Cortes, J; Curigliano, G; Musolino, A; Pegram, MD; Bachelot, T; Wright, GS; Saura, C; Escrivá de Romaní, S; De Laurentiis, M; Schwartz, GN; Pluard, TJ; Ricci, F; Gwin, WR; 3rd; Levy, C; Brown Glaberman, U; Ferrero, JM; ...Mais
PUBLICAÇÃO: 2023, FONTE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 41, NÚMERO: 2
AUTORES: Rugo, HS; Im, SA; Cardoso, F; Cortes, J; Curigliano, G; Musolino, A; Pegram, MD; Bachelot, T; Wright, GS; Saura, C; Escrivá de Romaní, S; De Laurentiis, M; Schwartz, GN; Pluard, TJ; Ricci, F; Gwin, WR; 3rd; Levy, C; Brown Glaberman, U; Ferrero, JM; ...Mais
PUBLICAÇÃO: 2023, FONTE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 41, NÚMERO: 2
INDEXADO EM: 
Scopus 
WOS
Scopus WOS2
TÃTULO: Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2-advanced breast cancer: a matching-adjusted indirect comparison
AUTORES: Rugo, Hope S. S.; Harmer, Victoria; O'Shaughnessy, Joyce; Jhaveri, Komal; Tolaney, Sara M. M.; Cardoso, Fatima; Bardia, Aditya; Maheshwari, Vikalp Kumar; Tripathi, Sandeep; Haftchenary, Sina; Pathak, Purnima; Fasching, Peter A. A.;
PUBLICAÇÃO: 2023, FONTE: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, VOLUME: 15
AUTORES: Rugo, Hope S. S.; Harmer, Victoria; O'Shaughnessy, Joyce; Jhaveri, Komal; Tolaney, Sara M. M.; Cardoso, Fatima; Bardia, Aditya; Maheshwari, Vikalp Kumar; Tripathi, Sandeep; Haftchenary, Sina; Pathak, Purnima; Fasching, Peter A. A.;
PUBLICAÇÃO: 2023, FONTE: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, VOLUME: 15
INDEXADO EM: Scopus WOS
Scopus WOS3
TÃTULO: XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
AUTORES: Schmid, Peter; Cortes, Javier; Joaquim, Ana; Janez, Noelia Martinez; Morales, Serafin; Diaz Redondo, Tamara; Blau, Sibel; Neven, Patrick; Lemieux, Julie; Garcia Saenz, Jose Angel; Hart, Lowell; Biyukov, Tsvetan; Baktash, Navid; Massey, Dan; Burris, Howard A., III; Rugo, Hope S.;
PUBLICAÇÃO: 2023, FONTE: BREAST CANCER RESEARCH, VOLUME: 25, NÚMERO: 1
AUTORES: Schmid, Peter; Cortes, Javier; Joaquim, Ana; Janez, Noelia Martinez; Morales, Serafin; Diaz Redondo, Tamara; Blau, Sibel; Neven, Patrick; Lemieux, Julie; Garcia Saenz, Jose Angel; Hart, Lowell; Biyukov, Tsvetan; Baktash, Navid; Massey, Dan; Burris, Howard A., III; Rugo, Hope S.;
PUBLICAÇÃO: 2023, FONTE: BREAST CANCER RESEARCH, VOLUME: 25, NÚMERO: 1
INDEXADO EM: Scopus WOS
Scopus WOS4
TÃTULO: Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2-Advanced Breast Cancer: Findings From a Multicountry Survey
AUTORES: Cardoso, Fatima; Rihani, Julie; Harmer, Victoria; Harbeck, Nadia; Casas, Ana; Rugo, Hope S.; Fasching, Peter A.; Moore, Adam; de Courcy, Joanna; Pathak, Purnima; Haftchenary, Sina; Aubel, Dawn; Schumacher Wulf, Eva;
PUBLICAÇÃO: 2023, FONTE: ONCOLOGIST, VOLUME: 28, NÚMERO: 10
AUTORES: Cardoso, Fatima; Rihani, Julie; Harmer, Victoria; Harbeck, Nadia; Casas, Ana; Rugo, Hope S.; Fasching, Peter A.; Moore, Adam; de Courcy, Joanna; Pathak, Purnima; Haftchenary, Sina; Aubel, Dawn; Schumacher Wulf, Eva;
PUBLICAÇÃO: 2023, FONTE: ONCOLOGIST, VOLUME: 28, NÚMERO: 10
INDEXADO EM: Scopus WOS
Scopus WOS5
TÃTULO: Poster Discussion Session Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/ human epidermal growth factor receptor-negative (HR+/HER2-) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC).
AUTORES: Rugo, Hope S.; O'Shaughnessy, Joyce; Jhaveri, Komal L.; Tolaney, Sara M.; Cardoso, Fatima; Bardia, Aditya; Maheshwari, Vikalp Kumar; Tripathi, Sandeep; Pathak, Purnima; Haftchenary, Sina; Fasching, Peter A.;
PUBLICAÇÃO: 2022, FONTE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 40, NÚMERO: 16
AUTORES: Rugo, Hope S.; O'Shaughnessy, Joyce; Jhaveri, Komal L.; Tolaney, Sara M.; Cardoso, Fatima; Bardia, Aditya; Maheshwari, Vikalp Kumar; Tripathi, Sandeep; Pathak, Purnima; Haftchenary, Sina; Fasching, Peter A.;
PUBLICAÇÃO: 2022, FONTE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 40, NÚMERO: 16
INDEXADO EM: WOS
WOS6
TÃTULO: KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer
AUTORES: Rugo, Hope S.; Sohn, Joohyuk; Jerez Gilarranz, Yolanda; Gonzalez Cortijo, Lucia; Sonnenblick, Amir; Sabanathan, Dhanusha; Pablo Korbenfeld, Ernesto; Egle, Daniel; Poirier, Brigitte; Zagouri, Flora; Matikas, Alexios; Aksoy, Sercan; Demirci, Umut; Ramos Elias, Pier; Im, Seock Ah; Cardoso, Fatima; Jia, Liyi; Baccan, Carlos; Tryfonidis, Konstantinos; Schmid, Peter;
PUBLICAÇÃO: 2022, FONTE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 40, NÚMERO: 16
AUTORES: Rugo, Hope S.; Sohn, Joohyuk; Jerez Gilarranz, Yolanda; Gonzalez Cortijo, Lucia; Sonnenblick, Amir; Sabanathan, Dhanusha; Pablo Korbenfeld, Ernesto; Egle, Daniel; Poirier, Brigitte; Zagouri, Flora; Matikas, Alexios; Aksoy, Sercan; Demirci, Umut; Ramos Elias, Pier; Im, Seock Ah; Cardoso, Fatima; Jia, Liyi; Baccan, Carlos; Tryfonidis, Konstantinos; Schmid, Peter;
PUBLICAÇÃO: 2022, FONTE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 40, NÚMERO: 16
INDEXADO EM: WOS
WOS7
TÃTULO: Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
AUTORES: Ueno, N. T.; Jacot, W.; Yamashita, T.; Sohn, J.; Tokunaga, E.; Prat, A.; Tsurutani, J.; Park, Y. H.; Rugo, H. S.; Xu, B.; Cardoso, F.; Mitri, Z.; Mahtani, R.; Dunton, K.; Wang, Y.; Gambhire, D.; Cottone, F.; Harbeck, N.; Cameron, D. A.; Modi, S.;
PUBLICAÇÃO: 2022, FONTE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 33, NÚMERO: 7
AUTORES: Ueno, N. T.; Jacot, W.; Yamashita, T.; Sohn, J.; Tokunaga, E.; Prat, A.; Tsurutani, J.; Park, Y. H.; Rugo, H. S.; Xu, B.; Cardoso, F.; Mitri, Z.; Mahtani, R.; Dunton, K.; Wang, Y.; Gambhire, D.; Cottone, F.; Harbeck, N.; Cameron, D. A.; Modi, S.;
PUBLICAÇÃO: 2022, FONTE: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) in ANNALS OF ONCOLOGY, VOLUME: 33, NÚMERO: 7
INDEXADO EM: WOS
WOS8
TÃTULO: Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
AUTORES: Rugo, HS; Im, SA; Cardoso, F; Cortes, J; Curigliano, G; Musolino, A; Pegram, MD; Wright, GS; Saura, C; Escriva de Romani, S; De Laurentiis, M; Levy, C; Brown Glaberman, U; Ferrero, JM; de Boer, M; Kim, SB; Petrakova, K; Yardley, DA; Freedman, O; Jakobsen, EH; ...Mais
PUBLICAÇÃO: 2021, FONTE: JAMA ONCOLOGY
AUTORES: Rugo, HS; Im, SA; Cardoso, F; Cortes, J; Curigliano, G; Musolino, A; Pegram, MD; Wright, GS; Saura, C; Escriva de Romani, S; De Laurentiis, M; Levy, C; Brown Glaberman, U; Ferrero, JM; de Boer, M; Kim, SB; Petrakova, K; Yardley, DA; Freedman, O; Jakobsen, EH; ...Mais
PUBLICAÇÃO: 2021, FONTE: JAMA ONCOLOGY
INDEXADO EM: Scopus WOS
Scopus WOS9
TÃTULO: Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer Full Text
AUTORES: Jackisch, C; Barcenas, CH; Bartsch, R; Di Palma, J; Gluck, S; Harbeck, N; Macedo, G; O'Shaughnessy, J; Pistilli, B; Ruiz Borrego, M; Rugo, HS;
PUBLICAÇÃO: 2021, FONTE: CLINICAL BREAST CANCER, VOLUME: 21, NÚMERO: 5
AUTORES: Jackisch, C; Barcenas, CH; Bartsch, R; Di Palma, J; Gluck, S; Harbeck, N; Macedo, G; O'Shaughnessy, J; Pistilli, B; Ruiz Borrego, M; Rugo, HS;
PUBLICAÇÃO: 2021, FONTE: CLINICAL BREAST CANCER, VOLUME: 21, NÚMERO: 5
INDEXADO EM: Scopus WOS
Scopus WOS10
TÃTULO: Phase 3 SOPHIA study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in patients with HER2+metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis
AUTORES: Hope S Rugo; Seock Ah Im; Fatima Cardoso; Javier Cortes; Giuseppe Curigliano; Mark D Pegram; Antonino Musolino; Thomas Bachelot; Gail S Wright; Michelino De laurentiis; Peter A Kaufman; Timothy Pluard; Francesco Ricci; Lupe G Salazar; Denise A Yardley; Sutton Edlich; Shengyan Y Hong; Edwin Rock; William J Gradishar;
PUBLICAÇÃO: 2020, FONTE: San Antonio Breast Cancer Symposium in CANCER RESEARCH, VOLUME: 80, NÚMERO: 4
AUTORES: Hope S Rugo; Seock Ah Im; Fatima Cardoso; Javier Cortes; Giuseppe Curigliano; Mark D Pegram; Antonino Musolino; Thomas Bachelot; Gail S Wright; Michelino De laurentiis; Peter A Kaufman; Timothy Pluard; Francesco Ricci; Lupe G Salazar; Denise A Yardley; Sutton Edlich; Shengyan Y Hong; Edwin Rock; William J Gradishar;
PUBLICAÇÃO: 2020, FONTE: San Antonio Breast Cancer Symposium in CANCER RESEARCH, VOLUME: 80, NÚMERO: 4
INDEXADO EM: WOS
WOS